ArticleFrontiers in pediatrics2025
Acute ataxia in children: etiological spectrum and clinical characteristics.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Movement Disorders in MOGAD: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Relapsing Seronegative Immune-Mediated Cerebellar Ataxia with Evolving Intrathecal Immune Activation and Rituximab Consolidation in a Toddler: A Case Report.Cerebellum (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute ataxia is one of the most common movement disorders in children, characterized by complex etiologies, some of which may lead to disability or life-threatening complications. Early diagnosis and intervention are therefore crucial. Objective: This study aimed to investigate the etiological spectrum and clinical characteristics of children presenting with acute ataxia as the initial symptom. Methods: A retrospective analysis was conducted on children hospitalized at Hebei Children's Hospital between January 2018 and December 2024, all of whom exhibited acute ataxia as the primary manifestation. Clinical data, including etiology, age distribution, and laboratory findings, were systematically reviewed and analyzed. Results: A total of 257 children were included, with a male-to-female ratio of 1.14:1 and a median age of onset of 3 years (range: 10 months to 14 years). Initial screening of 315 records identified 58 patients for exclusion. Etiologies varied by age: infants/toddlers (0-3 years) showed acute postinfectious cerebellar ataxia (APCA, 66%), drug intoxication (14%), and acute disseminated encephalomyelitis (ADEM, 8%); preschoolers (4-6 years) had APCA (63%), ADEM (14%), and acute cerebellitis (AC, 8%); school-aged children (7-14 years) presented APCA (48%), AC (21%), and drug intoxication (14%). AC patients exhibited later onset, longer duration from symptom onset to hospital presentation, and more frequent neurological symptoms (encephalopathy, headache, vomiting) compared to APCA. Cerebrospinal fluid (CSF) nucleated cell counts were elevated in AC. Among APCA cases, CSF oligoclonal band (OCB)-positive patients had later onset, extended hospitalization, higher CSF nucleated cell counts, and higher relapse rates. Autoantibody screening in a subset of 135 patients identified CSF OCB, serum myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG), GQ1b, and aquaporin-4 (AQP4) antibodies as common markers. Conclusion: The etiology of acute ataxia in children varies significantly by age, necessitating tailored diagnostic approaches. For cases suggestive of central nervous system demyelination or recurrent ataxia, comprehensive evaluations, including autoantibody testing, tumor screening, and genetic/metabolic assessments, should be considered to guide management and improve outcomes. CSF OCB positivity may identify an APCA subgroup with more pronounced inflammatory features and a potentially higher relapse risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.